$RSG

Insider Stock Purchases: September 15, 2026

On September 15, 2026, 162 insider stock purchases were reported. Notable transactions include Cascade Investment buying 176,547 shares of Republic Services (RSG) for $39.4M, Tricor PMT25 Holdings buying 525,000 shares of CPI Card Group (PMTS) for $11.3M, and Devon Energy (DVN) CEO buying 3,913 shares for $199,876.

Original reporting
Published Sep 15, 2026, 6:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Stock Purchases: September 15, 2026 — source image
Decision brief

The 30-second read

$RSGBullishMed
01

Why it matters

Aggregated insider buying suggests selective confidence among executives, potentially foreshadowing positive earnings or strategic moves.

02

Market read

Insider activity across diverse sectors may influence short‑term trading decisions for each ticker.

03

What to watch

Recent earnings beats or upcoming regulatory filings may be driving the buying, not captured in the article.

Relevance 6/10Novelty 6/10Timing: as of Sep 15 2026 (today)

Background

The article aggregates recent Form 4 insider transactions reported by QuiverQuant for several U.S. listed companies.

Company-level read

Ticker impact

$RSGBullishHigh confidence
Context

Cascade Investment bought 176,547 shares of Republic Services for $39.4M on 09/11, indicating strong insider buying.

Expected impact

Potential short-term upside as market absorbs buying pressure.

Evidence & confidence

C‑suite and major insider accumulated over 6.7M shares worth $1.46B in the past six months.

$PMTSBullishMedium confidence
Context

Tricor PMT25 Holdings purchased 525,000 CPI Card Group shares for $11.3M on 09/14, a sizable insider stake.

Expected impact

Likely modest price support in the near term.

Evidence & confidence

Insider purchases exceed $10M, notable for a small‑cap lender.

$RWTBullishMedium confidence
Context

CEO Christopher J. Abate bought 100,000 Redwood Trust shares for $383,900 on 09/15.

Expected impact

May trigger short‑term buying interest.

Evidence & confidence

C‑suite buying aligns with recent capital‑raising activities.

$DVNNeutralLow confidence
Context

Devon Energy President/CEO Clay M. Gaspar purchased 3,913 shares for $199,876 on 09/14.

Expected impact

Limited impact; likely absorbed without major price move.

Evidence & confidence

Purchase size is small relative to market cap.

$MAIABullishMedium confidence
Context

CEO Vlad Vitoc bought 73,000 Maia Biotechnology shares for $100,010 on 09/14.

Expected impact

Potential upside if upcoming trial data is favorable.

Evidence & confidence

Insider purchases total over $250K in recent months for a micro‑cap.

Market effects

Insider buying across waste services, credit cards, REITs, energy, and biotech may hint at sector‑wide confidence.

U.S. equity markets, especially small‑cap and dividend‑focused segments.

Limited to U.S. listed companies; no direct global macro effect.

Counterpoint

Insider purchases could be routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • Republic Services, Inc.

    Waste management firm (NYSE:RSG).

  • CPI Card Group, Inc.

    Credit card issuer (NASDAQ:PMTS).

  • Redwood Trust, Inc.

    Mortgage REIT (NASDAQ:RWT).

  • Devon Energy Corp.

    Energy producer (NYSE:DVN).

  • Maia Biotechnology, Inc.

    Biotech firm (NASDAQ:MAIA).

Related articles

$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

$WMBMedAI 8/10

There’s a pipeline of deals—for pipelines—that will help power the AI boom

Midstream energy sector sees increased deal activity due to high demand for infrastructure, particularly in natural gas. Recent acquisitions include ONEOK's $4.42B purchase of Brazos Midstream's Permian Basin assets and Williams' $5.5B acquisition of Momentum Midstream. A bipartisan infrastructure bill could further expedite energy projects, benefiting the AI boom.

$BPHighAI 8/10

BP vs. Devon (DVN): A Shale Deal That Never Happened Shows Two Different Reset Stories

BP considered acquiring Devon Energy's Eagle Ford assets but ultimately withdrew. BP shares fell 3.4% on Friday, while Devon rose 1.8% on Thursday. Both companies' stocks are up nearly 30% this year, trading below 10 times forward earnings. BP's progress is tied to oil prices and deleveraging, while Devon focuses on asset disposals and synergies. Analysts have mixed views on both companies' outlooks.